Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended-Release
- W. Timothy Garvey, MD1⇑,
- Donna H. Ryan, MD2,
- Robert Henry, MD3,
- Nancy J.V. Bohannon, MD4,
- Hermann Toplak, MD5,
- Michael Schwiers, MS6,
- Barbara Troupin, MD7 and
- Wesley W. Day, PhD7
- 1Department of Nutrition Sciences, University of Alabama at Birmingham and the Birmingham VA Medical Center, Birmingham, Alabama, USA;
- 2Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA;
- 3University of California San Diego School of Medicine and the San Diego VA Medical Center, San Diego, California, USA;
- 4Monteagle Medical Center, San Francisco, California, USA;
- 5Medical University of Graz, Graz, Austria;
- 6Medpace, Cincinnati, Ohio, USA;
- 7VIVUS, Inc., Mountain View, California, USA
- Corresponding Author: W. Timothy Garvey, Email: ).
Objective To evaluate over 108 weeks the effect of phentermine and topiramate extended-release (PHEN/TPM ER) treatment on progression to type 2 diabetes and/or cardiometabolic disease in subjects with Prediabetes and/or Metabolic Syndrome (MetS) at baseline.
Research Design and Methods Subanalysis of a Phase 3, randomized, placebo-controlled, double-blind study of overweight/obese subjects (BMI ≥27 to ≤45 kg/m2) with ≥2 comorbidities. Subjects were randomized to placebo, PHEN 7.5mg/TPM ER 46mg (7.5/46), or PHEN 15mg/TPM ER 92mg (15/92) plus lifestyle modifications for 108 weeks. Percent weight loss in the intent-to-treat population using multiple imputation (ITT-MI), annualized incidence rate of progression to type 2 diabetes, and changes in glycemia, lipid parameters, blood pressure, and waist circumference were evaluated.
Results At baseline, 475 subjects met the criteria for Prediabetes and/or MetS. After 108 weeks, subjects with Prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5%, 10.9%, and 12.1%, respectively (ITT-MI; P < 0.0001 vs placebo associated with reductions of 70.5% and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT; P < 0.05),versus placebo, which was related to degree of weight lost and was accompanied by significant improvements in cardiometabolic parameters. PHEN/TPM ER was well tolerated by this subgroup over 2 years.
Conclusions PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with Prediabetes and/or MetS, accompanied by improvements in multiple cardiometabolic disease risk factors.
- Received June 27, 2013.
- Accepted September 27, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.